Lexicon Pharmaceuticals (LXRX) Expected to Announce Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $6.48 million for the quarter. Investors interested in listening to the company's conference call can do so using this link.

Lexicon Pharmaceuticals Trading Up 5.7 %

NASDAQ LXRX traded up $0.02 during trading hours on Thursday, reaching $0.36. The company's stock had a trading volume of 7,034,814 shares, compared to its average volume of 3,962,775. Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.83. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The stock has a market cap of $87.41 million, a P/E ratio of -0.47 and a beta of 1.04. The firm has a fifty day simple moving average of $0.74 and a 200-day simple moving average of $1.16.

Wall Street Analysts Forecast Growth

LXRX has been the topic of a number of recent research reports. Leerink Partners reiterated a "market perform" rating and set a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday. HC Wainwright restated a "buy" rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday. Finally, Leerink Partnrs cut Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $2.50.

Remove Ads

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lexicon Pharmaceuticals stock. Bank of America Corp DE increased its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 27.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 136,407 shares of the biopharmaceutical company's stock after purchasing an additional 29,319 shares during the period. Bank of America Corp DE owned approximately 0.06% of Lexicon Pharmaceuticals worth $101,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.